Cognitive Inflexibility after Prefrontal Serotonin Depletion

Science

Volumn 304, Issue 5672, 2004, Pages 878-880

  Clarke, H F ^a   Dalley, J W ^a   Crofts, H S ^a   Robbins, T W ^a   Roberts, A C ^b  

^a UK   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; COGNITIVE SYSTEMS; DISEASES; DRUG PRODUCTS;

NEUROPSYCHIATRIC DISORDERS; PREFRONTAL CORTEX (PFC);

NEUROPHYSIOLOGY;

SEROTONIN;

BIOLOGY; MEDICINE;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; DISCRIMINATION LEARNING; MONKEY; NEUROPSYCHOLOGY; NONHUMAN; PERSEVERATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; TASK PERFORMANCE;

5,7-DIHYDROXYTRYPTAMINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CALLITHRIX; COGNITION; DISCRIMINATION LEARNING; DOPAMINE; FEMALE; FRONTAL LOBE; GYRUS CINGULI; HYDROXYINDOLEACETIC ACID; MALE; MOTOR CORTEX; NOREPINEPHRINE; OXIDOPAMINE; PREFRONTAL CORTEX; PSYCHOMOTOR PERFORMANCE; REWARD; SEROTONIN;

ANIMALIA; MARMOSETS;

EID: 2442503749     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1094987     Document Type: Article

References (30)

1. W. F. Baare et al., Biol. Psychiatry 45, 1597 (1999).
2. T. R. Insel, J. T. Winslow, Psychiatr, Clin. North Am. 15, 813 (1992).
3. H. S. Mayberg et al., Neuroreport 8, 1057 (1997).
4. U. D. McCann, V. Eligulashvili, G. A. Ricaurte, Neuropsychobiology 42, 11 (2000).
5. J. M. Wilson et al., Nature Med. 2, 699 (1996).
6. S. B. Park et al., Neuropharmacology 33, 575 (1994).
7. S. Mobini, T. J. Chiang, M. Y. Ho, C. M. Bradshaw, E. Szabadi, Psychopharmacology (Berlin) 152, 390 (2000).
8. R. D. Rogers et al., Psychopharmacology (Berlin) 146, 482 (1999).
9. R. Dias, T. W. Robbins, A. C. Roberts, Nature 380, 69 (1996).
10. B. Jones, M. Mishkin, Exp. Neurol. 36, 362 (1972).
11. L. K. Fellows, M. J. Farah, Brain 126, 1830 (2003).
12. Materials and methods are available as supporting material on Science Online.
13. M. Freedman, S. Black P. Ebert, M. Binns, Cereb. Cortex 8, 18 (1998).
14. R. D. Rogers et al., Neuropsychopharmacology 28, 153 (2003).
15. H. Hardin et al., Brain Res. Mol. Brain Res. 26, 1 (1994).
16. H. S. Crofts et al., Cereb. Cortex 11, 1015 (2001).
17. G. W. Handley, W. H. Calhoun, Psychopharmacology (Berlin) 57, 115 (1978).
18. R. M. Ridley, T. A. Haystead, H. F. Baker, T. J. Crow, Pharmacol. Biochem. Behav. 14, 849 (1981).
19. A. C. Roberts et al., Neuroscience 34, 311 (1990).
20. A. C. Roberts, T. W. Robbins, B. J. Everitt, J. L. Muir, Neuroscience 47, 251 (1992).
21. H. Hirano, J. Day, H. C. Fibiger, J. Neurochem. 65, 1139 (1995).
22. G. Schoenbaum, A. A. Chiba, M. Gallagher, J. Neurosci. 19, 1876 (1999).
23. E. T. Rolls. Cereb. Cortex 10, 284 (2000).
24. J. O'Doherty, M. L. Kringelbach, E. T. Rolls, J. Hornak C. Andrews, Nature Neurosci. 4, 95 (2001).
25. A. Bechara, H. Damasio, A. R. Damasio, Cereb. Cortex 10, 295 (2000).
26. H. Hermesh et al., Eur. Neuropsychopharmacol. 13, 87 (2003).
27. J. Zohar, R. Judge, Br. J. Psychiatry 169, 468 (1996).
28. C. Pentelis et al., Schizophr. Res. 37, 251 (1999).
29. J. D. Jentsch, P. Olausson, R. De La Garza 2nd, J. R. Taylor, Neuropsychopharmacology 26, 183 (2002).
30. We thank D. Theobald for histochemical assistance and R. Cardinal and S. Walker for valuable advice. Supported by a Wellcome Trust program grant (to T.W.R., B. J. Everitt, A.C.R. and B. J. Sahakian) and conducted within the Medical Research Council Centre for Behavioral and Clinical Neuroscience H.F.C. was supported by a Wellcome Trust Prize Studentship.